{"pmid":32245885,"title":"Learning from our immunological history: What can SARS-CoV teach us about SARS-CoV-2?","text":["Learning from our immunological history: What can SARS-CoV teach us about SARS-CoV-2?","Many strategies are being deployed to rapidly uncover targetable mechanisms of infection for SARS-CoV-2, and Hoffman et al exploit our understanding and immunological experience with SARS-CoV in our global race to understand, mitigate, and eventually prevent COVID-19.","Sci Immunol","Henrickson, Sarah E","32245885"],"abstract":["Many strategies are being deployed to rapidly uncover targetable mechanisms of infection for SARS-CoV-2, and Hoffman et al exploit our understanding and immunological experience with SARS-CoV in our global race to understand, mitigate, and eventually prevent COVID-19."],"journal":"Sci Immunol","authors":["Henrickson, Sarah E"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245885","week":"202014|Mar 30 - Apr 05","doi":"10.1126/sciimmunol.abb8618","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1663169699609837569,"score":7.6048946,"similar":[{"pmid":32106567,"title":"Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.","text":["Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.","The beginning of 2020 has seen the emergence of COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is an imminent need to better understand this new virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against SARS-CoV-2 by considering the high genetic similarity between SARS-CoV-2 and SARS-CoV, which caused the outbreak in 2003, and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to SARS-CoV-2 proteins. As no mutation has been observed in these identified epitopes among the 120 available SARS-CoV-2 sequences (as of 21 February 2020), immune targeting of these epitopes may potentially offer protection against this novel virus. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against SARS-CoV-2.","Viruses","Ahmed, Syed Faraz","Quadeer, Ahmed A","McKay, Matthew R","32106567"],"abstract":["The beginning of 2020 has seen the emergence of COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is an imminent need to better understand this new virus and to develop ways to control its spread. In this study, we sought to gain insights for vaccine design against SARS-CoV-2 by considering the high genetic similarity between SARS-CoV-2 and SARS-CoV, which caused the outbreak in 2003, and leveraging existing immunological studies of SARS-CoV. By screening the experimentally-determined SARS-CoV-derived B cell and T cell epitopes in the immunogenic structural proteins of SARS-CoV, we identified a set of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins that map identically to SARS-CoV-2 proteins. As no mutation has been observed in these identified epitopes among the 120 available SARS-CoV-2 sequences (as of 21 February 2020), immune targeting of these epitopes may potentially offer protection against this novel virus. For the T cell epitopes, we performed a population coverage analysis of the associated MHC alleles and proposed a set of epitopes that is estimated to provide broad coverage globally, as well as in China. Our findings provide a screened set of epitopes that can help guide experimental efforts towards the development of vaccines against SARS-CoV-2."],"journal":"Viruses","authors":["Ahmed, Syed Faraz","Quadeer, Ahmed A","McKay, Matthew R"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32106567","week":"20209|Feb 24 - Mar 01","doi":"10.3390/v12030254","keywords":["*2019 novel coronavirus","*2019-nCoV","*B cell epitopes","*COVID-19","*Coronavirus","*MERS-CoV","*SARS-CoV","*SARS-CoV-2","*T cell epitopes","*vaccine"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1663095626134454273,"score":100.060616},{"pmid":32245083,"title":"SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far.","text":["SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far.","In December 2019, a cluster of fatal pneumonia cases presented in Wuhan, China. They were caused by a previously unknown coronavirus. All patients had been associated with the Wuhan Wholefood market, where seafood and live animals are sold. The virus spread rapidly and public health authorities in China initiated a containment effort. However, by that time, travelers had carried the virus to many countries, sparking memories of the previous coronavirus epidemics, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and causing widespread media attention and panic. Based on clinical criteria and available serological and molecular information, the new disease was called coronavirus disease of 2019 (COVID-19), and the novel coronavirus was called SARS Coronavirus-2 (SARS-CoV-2), emphasizing its close relationship to the 2002 SARS virus (SARS-CoV). The scientific community raced to uncover the origin of the virus, understand the pathogenesis of the disease, develop treatment options, define the risk factors, and work on vaccine development. Here we present a summary of current knowledge regarding the novel coronavirus and the disease it causes.","Pathogens","Rabi, Firas A","Al Zoubi, Mazhar S","Kasasbeh, Ghena A","Salameh, Dunia M","Al-Nasser, Amjad D","32245083"],"abstract":["In December 2019, a cluster of fatal pneumonia cases presented in Wuhan, China. They were caused by a previously unknown coronavirus. All patients had been associated with the Wuhan Wholefood market, where seafood and live animals are sold. The virus spread rapidly and public health authorities in China initiated a containment effort. However, by that time, travelers had carried the virus to many countries, sparking memories of the previous coronavirus epidemics, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), and causing widespread media attention and panic. Based on clinical criteria and available serological and molecular information, the new disease was called coronavirus disease of 2019 (COVID-19), and the novel coronavirus was called SARS Coronavirus-2 (SARS-CoV-2), emphasizing its close relationship to the 2002 SARS virus (SARS-CoV). The scientific community raced to uncover the origin of the virus, understand the pathogenesis of the disease, develop treatment options, define the risk factors, and work on vaccine development. Here we present a summary of current knowledge regarding the novel coronavirus and the disease it causes."],"journal":"Pathogens","authors":["Rabi, Firas A","Al Zoubi, Mazhar S","Kasasbeh, Ghena A","Salameh, Dunia M","Al-Nasser, Amjad D"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245083","week":"202014|Mar 30 - Apr 05","doi":"10.3390/pathogens9030231","keywords":["COVID-19","Coronavirus","SARS","SARS-CoV-2","Wuhan","pandemic"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment","Diagnosis"],"weight":1,"_version_":1663169699597254656,"score":93.18906},{"pmid":32225175,"title":"Structural basis of receptor recognition by SARS-CoV-2.","text":["Structural basis of receptor recognition by SARS-CoV-2.","A novel SARS-like coronavirus (SARS-CoV-2) recently emerged and is rapidly spreading in humans(1,2). A key to tackling this epidemic is to understand the virus's receptor recognition mechanism, which regulates its infectivity, pathogenesis and host range. SARS-CoV-2 and SARS-CoV recognize the same receptor - human ACE2 (hACE2)(3,4). Here we determined the crystal structure of the SARS-CoV-2 receptor-binding domain (RBD) (engineered to facilitate crystallization) in complex with hACE2. Compared with the SARS-CoV RBD, a hACE2-binding ridge in SARS-CoV-2 RBD takes a more compact conformation; moreover, several residue changes in SARS-CoV-2 RBD stabilize two virus-binding hotspots at the RBD/hACE2 interface. These structural features of SARS-CoV-2 RBD enhance its hACE2-binding affinity. Additionally, we show that RaTG13, a bat coronavirus closely related to SARS-CoV-2, also uses hACE2 as its receptor. The differences among SARS-CoV-2, SARS-CoV and RaTG13 in hACE2 recognition shed light on potential animal-to-human transmission of SARS-CoV-2. This study provides guidance for intervention strategies targeting receptor recognition by SARS-CoV-2.","Nature","Shang, Jian","Ye, Gang","Shi, Ke","Wan, Yushun","Luo, Chuming","Aihara, Hideki","Geng, Qibin","Auerbach, Ashley","Li, Fang","32225175"],"abstract":["A novel SARS-like coronavirus (SARS-CoV-2) recently emerged and is rapidly spreading in humans(1,2). A key to tackling this epidemic is to understand the virus's receptor recognition mechanism, which regulates its infectivity, pathogenesis and host range. SARS-CoV-2 and SARS-CoV recognize the same receptor - human ACE2 (hACE2)(3,4). Here we determined the crystal structure of the SARS-CoV-2 receptor-binding domain (RBD) (engineered to facilitate crystallization) in complex with hACE2. Compared with the SARS-CoV RBD, a hACE2-binding ridge in SARS-CoV-2 RBD takes a more compact conformation; moreover, several residue changes in SARS-CoV-2 RBD stabilize two virus-binding hotspots at the RBD/hACE2 interface. These structural features of SARS-CoV-2 RBD enhance its hACE2-binding affinity. Additionally, we show that RaTG13, a bat coronavirus closely related to SARS-CoV-2, also uses hACE2 as its receptor. The differences among SARS-CoV-2, SARS-CoV and RaTG13 in hACE2 recognition shed light on potential animal-to-human transmission of SARS-CoV-2. This study provides guidance for intervention strategies targeting receptor recognition by SARS-CoV-2."],"journal":"Nature","authors":["Shang, Jian","Ye, Gang","Shi, Ke","Wan, Yushun","Luo, Chuming","Aihara, Hideki","Geng, Qibin","Auerbach, Ashley","Li, Fang"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32225175","week":"202014|Mar 30 - Apr 05","doi":"10.1038/s41586-020-2179-y","source":"PubMed","locations":["humans(1,2"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1662819280301850624,"score":71.74779},{"pmid":32244166,"title":"Why are pregnant women susceptible to COVID-19? An immunological viewpoint.","text":["Why are pregnant women susceptible to COVID-19? An immunological viewpoint.","The 2019 novel coronavirus disease (COVID-19) was first detected in December 2019 and became epidemic in Wuhan, Hubei Province, China. COVID-19 has been rapidly spreading out in China and all over the world. The virus causing COVID-19, SARS-CoV-2 has been known to be genetically similar to severe acute respiratory syndrome coronavirus (SARS-CoV) but distinct from it. Clinical manifestation of COVID-19 can be characterized by mild upper respiratory tract infection, lower respiratory tract infection involving non-life threatening pneumonia, and life-threatening pneumonia with acute respiratory distress syndrome. It affects all age groups, including newborns, to the elders. Particularly, pregnant women may be more susceptible to COVID-19 since pregnant women, in general, are vulnerable to respiratory infection. In pregnant women with COVID-19, there is no evidence for vertical transmission of the virus, but an increased prevalence of preterm deliveries has been noticed. The COVID-19 may alter immune responses at the maternal-fetal interface, and affect the well-being of mothers and infants. In this review, we focused on the reason why pregnant women are more susceptible to COVID-19 and the potential maternal and fetal complications from an immunological viewpoint.","J Reprod Immunol","Liu, Hong","Wang, Li-Ling","Zhao, Si-Jia","Kwak-Kim, Joanne","Mor, Gil","Liao, Ai-Hua","32244166"],"abstract":["The 2019 novel coronavirus disease (COVID-19) was first detected in December 2019 and became epidemic in Wuhan, Hubei Province, China. COVID-19 has been rapidly spreading out in China and all over the world. The virus causing COVID-19, SARS-CoV-2 has been known to be genetically similar to severe acute respiratory syndrome coronavirus (SARS-CoV) but distinct from it. Clinical manifestation of COVID-19 can be characterized by mild upper respiratory tract infection, lower respiratory tract infection involving non-life threatening pneumonia, and life-threatening pneumonia with acute respiratory distress syndrome. It affects all age groups, including newborns, to the elders. Particularly, pregnant women may be more susceptible to COVID-19 since pregnant women, in general, are vulnerable to respiratory infection. In pregnant women with COVID-19, there is no evidence for vertical transmission of the virus, but an increased prevalence of preterm deliveries has been noticed. The COVID-19 may alter immune responses at the maternal-fetal interface, and affect the well-being of mothers and infants. In this review, we focused on the reason why pregnant women are more susceptible to COVID-19 and the potential maternal and fetal complications from an immunological viewpoint."],"journal":"J Reprod Immunol","authors":["Liu, Hong","Wang, Li-Ling","Zhao, Si-Jia","Kwak-Kim, Joanne","Mor, Gil","Liao, Ai-Hua"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32244166","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jri.2020.103122","keywords":["COVID-19","Immunity","Maternal-fetal interface","Placenta","Pregnancy"],"source":"PubMed","locations":["Wuhan","China","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Diagnosis","Prevention"],"weight":1,"_version_":1663079112825110529,"score":69.45879},{"pmid":32245784,"title":"A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV.","text":["A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV.","The outbreak of COVID-19 caused by SARS-CoV-2 virus has now become a pandemic, but there is currently very little understanding of the antigenicity of the virus. We therefore determined the crystal structure of CR3022, a neutralizing antibody previously isolated from a convalescent SARS patient, in complex with the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein to 3.1 A. CR3022 targets a highly conserved epitope, distal from the receptor-binding site, that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. Structural modeling further demonstrates that the binding epitope can only be accessed by CR3022 when at least two RBD on the trimeric S protein are in the \"up\" conformation and slightly rotated. Overall, this study provides molecular insights into antibody recognition of SARS-CoV-2.","Science","Yuan, Meng","Wu, Nicholas C","Zhu, Xueyong","Lee, Chang-Chun D","So, Ray T Y","Lv, Huibin","Mok, Chris K P","Wilson, Ian A","32245784"],"abstract":["The outbreak of COVID-19 caused by SARS-CoV-2 virus has now become a pandemic, but there is currently very little understanding of the antigenicity of the virus. We therefore determined the crystal structure of CR3022, a neutralizing antibody previously isolated from a convalescent SARS patient, in complex with the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein to 3.1 A. CR3022 targets a highly conserved epitope, distal from the receptor-binding site, that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. Structural modeling further demonstrates that the binding epitope can only be accessed by CR3022 when at least two RBD on the trimeric S protein are in the \"up\" conformation and slightly rotated. Overall, this study provides molecular insights into antibody recognition of SARS-CoV-2."],"journal":"Science","authors":["Yuan, Meng","Wu, Nicholas C","Zhu, Xueyong","Lee, Chang-Chun D","So, Ray T Y","Lv, Huibin","Mok, Chris K P","Wilson, Ian A"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245784","week":"202014|Mar 30 - Apr 05","doi":"10.1126/science.abb7269","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663169699677995008,"score":68.65384}]}